Concentrations of the stress hormone copeptin increase upon hypoglycaemia in patients with type 1 diabetes dependent of hypoglycaemia awareness

Eleonora Seelig, Stefan Bilz, Ulrich Keller, Fabian Meienberg, Mirjam Christ-Crain, Eleonora Seelig, Stefan Bilz, Ulrich Keller, Fabian Meienberg, Mirjam Christ-Crain

Abstract

Objective: Copeptin, a marker for stress mirroring vasopressin concentrations, has been shown to increase upon insulin-induced hypoglycaemia in patients after transsphenoidal surgery of pituitary adenomas. Patients with type 1 diabetes mellitus are prone to hypoglycaemia, but no data about copeptin levels upon hypoglycaemia are available. Furthermore, the perception of hypoglycaemia can vary from total unawareness to disabling episodes. The aim of this study was to investigate whether copeptin increases upon hypoglycaemia in patients with type 1 diabetes mellitus and is associated with the degree of hypoglycaemia awareness.

Materials and methods: In this prospective observational study, 17 patients with type 1 diabetes underwent a standardized insulin infusion test. Blood sampling for glucose and copeptin was performed at baseline and after 60 minutes (min). To assess hypoglycaemia associated symptoms the Mood and Symptom Questionnaire (MSQ) was conducted at baseline and after 60 min.

Results: During insulin infusion, blood glucose decreased from 5.1 (SD±0.2) to 3.0 (±0.5) mmol/L at 60 min (p<0.001). Copeptin concentrations increased from 3.2 (±1.7) to 3.8 (±1.9) pmol/L (p = 0.03). Mood and Symptoms Questionnaire scores increased from 14 (±3.0) to 18 (±5.8), (p = 0.006). Patients with good hypoglycaemia awareness had an increase in copeptin from 3.0 (±1.8) to 4.2 (±2.4) pmol/L (p = 0.03) in contrast to patients more unaware of hypoglycaemia who only showed an increase in copeptin from 3.3 (±1.6) to 3.6 (±1.4) pmol/L (p = 0.4). There was a trend to a larger copeptin increase in patients aware of hypoglycemia compared to patients unaware of hypoglycemia (p = 0.074).

Conclusion: Copeptin increases in patients with type 1 diabetes upon insulin induced hypoglycaemia. Interestingly, the copeptin increase seems associated with the degree of hypoglycaemia awareness. This hypothesis warrants further verification.

Trial registration: ClinicalTrials.gov NCT00515801.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Recruitment of participants.
Figure 1. Recruitment of participants.
Figure 2. Copeptin and Hypoglycaemia Awareness.
Figure 2. Copeptin and Hypoglycaemia Awareness.
The increase of copeptin levels in patients with type 1 diabetes during hypoglycaemia depends on hypoglycaemia awareness. Patients more aware of hypoglycaemia (2a) had a significant increase in copeptin levels in contrast to patients with poor hypoglycaemia awareness (2b). Continuous variables are presented as mean (±standard deviation). Within group comparisons were analysed using paired t-test. Data were analysed using statistical software (Statistical Package for Social Sciences, IBM SPSS Version 20, Chicago IL).

References

    1. Cryer PE (2008) The barrier of hypoglycemia in diabetes. Diabetes 57: 3169–3176.
    1. Baylis PH, Heath DA (1977) Plasma-arginine-vasopressin response to insulin-induced hypoglycaemia. Lancet 2: 428–430.
    1. Tesfaye N, Seaquist ER (2010) Neuroendocrine responses to hypoglycemia. Ann N Y Acad Sci 1212: 12–28.
    1. Fisher BM, Baylis PH, Thornton S, Frier BM (1989) Arginine vasopressin and oxytocin responses to insulin-induced hypoglycemia in type 1 (insulin-dependent) diabetes. J Clin Endocrinol Metab 68: 688–692.
    1. Antoni FA (1993) Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front Neuroendocrinol 14: 76–122.
    1. Muller B, Morgenthaler N, Stolz D, Schuetz P, Muller C, et al. (2007) Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 37: 145–152.
    1. Katan M, Fluri F, Morgenthaler NG, Schuetz P, Zweifel C, et al. (2009) Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol 66: 799–808.
    1. Morgenthaler NG, Muller B, Struck J, Bergmann A, Redl H, et al. (2007) Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 28: 219–226.
    1. Reichlin T, Hochholzer W, Stelzig C, Laule K, Freidank H, et al. (2009) Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol 54: 60–68.
    1. Katan M, Morgenthaler NG, Dixit KC, Rutishauser J, Brabant GE, et al. (2007) Anterior and posterior pituitary function testing with simultaneous insulin tolerance test and a novel copeptin assay. J Clin Endocrinol Metab 92: 2640–2643.
    1. Morgenthaler NG, Struck J, Alonso C, Bergmann A (2006) Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52: 112–119.
    1. Weinger K, Jacobson AM, Draelos MT, Finkelstein DM, Simonson DC (1995) Blood glucose estimation and symptoms during hyperglycemia and hypoglycemia in patients with insulin-dependent diabetes mellitus. Am J Med 98: 22–31.
    1. Scott LV, Dinan TG (1998) Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression. Life Sci 62: 1985–1998.
    1. Thompson CJ, Thow J, Jones IR, Baylis PH (1989) Vasopressin secretion during insulin-induced hypoglycaemia: exaggerated responses in people with type 1 diabetes. Diabet Med 6: 158–163.
    1. Robertson GL, Mahr EA, Athar S, Sinha T (1973) Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest 52: 2340–2352.
    1. Preibisz JJ, Sealey JE, Laragh JH, Cody RJ, Weksler BB (1983) Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension 5: I129–138.
    1. Struck J, Morgenthaler NG, Bergmann A (2005) Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides 26: 2500–2504.
    1. Cryer PE (2004) Diverse causes of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med 350: 2272–2279.

Source: PubMed

3
S'abonner